A Phase 2 Proof-of-Concept Study of the Combination of ACP-196 and Pembrolizumab in Subjects With Advanced Non-small Cell Lung Carcinoma

Trial Profile

A Phase 2 Proof-of-Concept Study of the Combination of ACP-196 and Pembrolizumab in Subjects With Advanced Non-small Cell Lung Carcinoma

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 07 Dec 2016

At a glance

  • Drugs Acalabrutinib (Primary) ; Pembrolizumab
  • Indications Non-small cell lung cancer
  • Focus Proof of concept; Therapeutic Use
  • Acronyms KEYNOTE166
  • Sponsors Acerta Pharma
  • Most Recent Events

    • 06 May 2016 Status changed from recruiting to active, no longer recruiting.
    • 20 May 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top